Become A Featured Company

Utah Selects Akerna to Run Its Seed-To-Sale Tracking Program

Ryan Allway

August 15th, 2019

News

DENVER, August 14, 2019 — Akerna Corp. (Nasdaq: KERN), a leading seed-to-sale regulatory compliance technology provider and developer of the cannabis industry’s first enterprise resource planning (ERP) software technology – MJ Platform®, announced today it has been awarded a new contract from the Utah Department of Health and Department of Agriculture to implement its seed-to-sale tracking platform, Leaf Data Systems® (Leaf Data) for Utah’s new medical cannabis program. Akerna also announced the launch of the next generation Leaf Data to combine a closed-loop platform with advanced tagging technology that evolves the category of government track-and-trace products, which first launches in Utah.

To create a closed-loop system, MJ Platform technology is the core of next generation Leaf Data and will be used by all Utah licensees as their primary cannabis tracking system at retail, wholesale, cultivation and manufacturing. MJ Platform, the cannabis industry’s first ERP, tracks cannabis at the gram and item level, as well as by-products and waste—from seed to product to shelf to patient/customer—through the complete supply chain. Leaf Data provides licensees initial exposure to MJ Platform and creates opportunities for further integration of MJ Platform’s richer functionality as business needs evolve.

To advance tagging technology, Leaf Data and solo sciences, inc, have partnered to launch solo*TAG™, the world’s first cryptographically-secure, cannabis product authentication system, exclusively for governments and only available with Leaf Data. This alternative to RFID tags is cheaper, more secure and more flexible for diverse packaging application.

“We are excited to launch our next generation of Leaf Data Systems in Utah. Closing the data loop and elevating tagging technology sets a new standard for government regulation with greater transparency and accountability, while providing cannabis licensees an affordable, secure and intuitive supply chain compliance framework,” stated Akerna Chief Executive Officer Jessica Billingsley.

“The inventory control and electronic verification systems are absolutely critical to the success of Utah’s medical cannabis program. Leaf Data provides the transparency and security to successfully launch Utah’s first program in cannabis,” commented Rich Oborn, Director of the Center for Medical Cannabis at the Utah Department of Health. “We look forward to implementing the advanced system for the safety of all Utah residents.”

Evolved Leaf Data Systems differentiators include:

  • Faster to implement – Leaf Data provides governments their requested data points and implements a working system quickly without lengthy and resource-intensive customization. As the only viable commercial-off-the-shelf (COTS) solution for cannabis traceability, Leaf Data can easily accommodate what are today large variances in the data points governments request for collection.
  • More transparency and accountability – The evolved Leaf Data product closes the loop between governments and licensees to eliminate alternate data collection sources, which reduces error, improves security and increases accountability. Data is also available within 15 minutes for real-time compliance.
  • Less cost to licensees – Current traceability tagging technology is costly and outdated. Solo science’s patented technology delivers an advanced solo*TAG as a unique digital fingerprint that eliminates the need for expensive technologies like holograms and RFID. The solo*TAG can also cost a fraction of the cost of current tagging technology, reducing some of the compliance cost burden for cannabis licensees.
  • Branding for export markets – As a government traceability product, solo*TAG has the unique ability to remain a secure digital fingerprint, while also authenticating a country’s product in a highly customizable, branded graphic. Unlike other authentication technologies, the solo*TAG can be applied to pre-existing products without the need for packaging redesign.
  • Mobile App – solo*TAG is mobile-app enabled, and Leaf Data is now the first mobile-enabled, seed-to-sale government traceability platform for cannabis businesses and for regulatory bodies.

“By partnering with Akerna, Utah will now have a first-of-its-kind, closed-loop intelligent authentication system to build consumer trust, and empower governments and brands with a 360° seed-to-self™ ecosystem to fulfill regulatory and compliance needs,” said Ashesh (Alex) Shah, CEO and founder of solo sciences.

The Utah solution also includes a partnership with MicroPact, provider of adaptive, COTS solutions to the public sector, to process patient and caregiver applications, renewals and payments while ensuring efficient registration and enforcement.

The evolved Leaf Data product gives governments a solution that’s faster to implement with reduced operating costs and less cost burden for licensees, while improving traceability and accountability. Globally, MJ Platform has adapted to 14 countries and the system operates in four languages and multiple currencies. Leaf Data currently supports state cannabis program operations that generate $722-million in taxes. Akerna currently has two bids pending for Leaf Data with growth opportunity into three additional states and 10-20 countries in the next two years.

About Akerna Corp.
Akerna is a regulatory compliance technology company in the cannabis space. The cornerstones of Akerna’s service offerings are MJ Platform® and Leaf Data Systems®, which are highly-versatile platforms that provide clients and government entities with a central data management system for tracking regulated cannabis products—from seed to product to shelf to customer—through the complete supply chain. Since establishment in 2010, the company has tracked more than $15 billion in cannabis sales across 14 countries and has served clients in 29 states across the U.S. As part of its business strategy, Akerna intends to grow through targeted, strategic acquisitions that are complementary to its current business and organically by accelerating its product development efforts. Akerna is based in Denver. More information is available online at www.akerna.com.

About solo sciences

Boston-based solo sciences provides instantaneous product authenticity reports via solo*, its proprietary technology offering, comprised of a secure tag, mobile app and backend system. The solo sciences mission is to build confidence and establish trust among consumers, while enabling retailers and distributors to close the loop with their suppliers. For more information, visit solosciences.com.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Akerna’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Akerna’s ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; costs related to the business combination; changes in applicable laws or regulations; the possibility that Akerna may be adversely affected by other economic, business, and/or competitive factors; Akerna’s ability to identify and integrate acquisitions and achieve expected synergies and operating efficiencies in connection with acquired businesses; and other risks and uncertainties indicated from time to time in the final prospectus of Akerna, including those under “Risk Factors” therein, and other documents filed or to be filed with the Securities and Exchange Commission (“SEC”) by Akerna.  Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those vary from forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information, cost savings, synergies and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. All information herein speaks only as of the date hereof, in the case of information about Akerna, or the date of such information, in the case of information from persons other than Akerna. Akerna undertakes no duty to update or revise the information contained herein. Forecasts and estimates regarding Akerna’s industry and end markets are based on sources we believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

Akerna Media Contact

Jon Goldberg / McKenna Miller

KCSA Strategic Communications

jgoldberg@kcsa.com / mmiller@kcsa.com

(212) 896-1282 / (347) 487-6197

Investor Contact

Phil Carlson / Scott Eckstein

KCSA Strategic Communications

pcarlson@kcsa.com / seckstein@kcsa.com

(212) 896-1233 / (212) 896-1210

solo sciences Media Contact

Kayla Abbassi

VSC on behalf of solo sciences

kayla@vscconsulting.com

Investor Contact

Vinay Shah

vinay@solosciences.com

(917) 885-2363

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading